Everett Harris & Co’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.78M Buy
61,038
+7,045
+13% +$568K 0.06% 81
2026
Q1
$4.68M Sell
53,993
-282
-0.5% -$27K 0.06% 83
2025
Q4
$5.21M Buy
54,275
+72
+0.1% +$6.99K 0.06% 77
2025
Q3
$5.16M Buy
54,203
+1,235
+2% +$114K 0.06% 73
2025
Q2
$4.62M Buy
52,968
+50
+0.1% +$4.24K 0.06% 78
2025
Q1
$4.76M Buy
52,918
+5,264
+11% +$471K 0.06% 76
2024
Q4
$3.81M Sell
47,654
-1,145
-2% -$99.1K 0.05% 83
2024
Q3
$4.39M Buy
48,799
+600
+1% +$50.5K 0.05% 75
2024
Q2
$3.79M Sell
48,199
-84
-0.2% -$6.89K 0.05% 80
2024
Q1
$4.21M Sell
48,283
-162
-0.3% -$13.8K 0.06% 75
2023
Q4
$3.99M Sell
48,445
-1,979
-4% -$151K 0.06% 77
2023
Q3
$3.95M Buy
50,424
+2,115
+4% +$177K 0.06% 72
2023
Q2
$4.26M Buy
48,309
+215
+0.4% +$18.5K 0.06% 72
2023
Q1
$3.88M Sell
48,094
-2,166
-4% -$177K 0.06% 73
2022
Q4
$3.91M Buy
50,260
+902
+2% +$73.1K 0.07% 73
2022
Q3
$3.99M Sell
49,358
-94,097
-66% -$8.46M 0.07% 69
2022
Q2
$12.9M Sell
143,455
-21,623
-13% -$2.19M 0.22% 50
2022
Q1
$18.3M Sell
165,078
-9,115
-5% -$963K 0.26% 47
2021
Q4
$18M Sell
174,193
-475
-0.3% -$55K 0.25% 48
2021
Q3
$21.9M Sell
174,668
-2,525
-1% -$327K 0.35% 40
2021
Q2
$22M Buy
177,193
+22
+0% +$2.76K 0.35% 43
2021
Q1
$20.9M Sell
177,171
-1,572
-0.9% -$184K 0.36% 41
2020
Q4
$20.9M Sell
178,743
-48
-0% -$5.28K 0.37% 40
2020
Q3
$18.6M Buy
178,791
+34,381
+24% +$3.45M 0.36% 41
2020
Q2
$13.2M Buy
144,410
+48,096
+50% +$4.61M 0.29% 44
2020
Q1
$8.69M Buy
96,314
+53,245
+124% +$5.66M 0.22% 48
2019
Q4
$4.89M Buy
43,069
+2,120
+5% +$233K 0.11% 67
2019
Q3
$4.45M Buy
40,949
+6,205
+18% +$647K 0.11% 67
2019
Q2
$3.38M Sell
34,744
-3,721
-10% -$340K 0.08% 76
2019
Q1
$3.5M Sell
38,465
-824
-2% -$73.7K 0.09% 73
2018
Q4
$3.57M Sell
39,289
-2,740
-7% -$256K 0.1% 66
2018
Q3
$4.13M Sell
42,029
-2,510
-6% -$232K 0.1% 64
2018
Q2
$3.81M Sell
44,539
-5,575
-11% -$466K 0.1% 66
2018
Q1
$4.02M Buy
50,114
+6,675
+15% +$551K 0.11% 62
2017
Q4
$3.51M Sell
43,439
-1,680
-4% -$135K 0.1% 75
2017
Q3
$3.51M Sell
45,119
-6,450
-13% -$536K 0.11% 72
2017
Q2
$4.58M Buy
51,569
+901
+2% +$76K 0.14% 63
2017
Q1
$4.08M Sell
50,668
-550
-1% -$43K 0.13% 66
2016
Q4
$3.65M Sell
51,218
-6,925
-12% -$544K 0.13% 66
2016
Q3
$5.02M Sell
58,143
-420
-0.7% -$36.6K 0.18% 60
2016
Q2
$5.08M Sell
58,563
-1,500
-2% -$121K 0.18% 63
2016
Q1
$4.5M Sell
60,063
-250
-0.4% -$18.8K 0.16% 64
2015
Q4
$4.64M Sell
60,313
-5,080
-8% -$382K 0.16% 61
2015
Q3
$4.38M Sell
65,393
-525
-0.8% -$38.7K 0.16% 66
2015
Q2
$4.88M Sell
65,918
-5,125
-7% -$392K 0.17% 64
2015
Q1
$5.54M Sell
71,043
-45
-0.1% -$3.41K 0.19% 59
2014
Q4
$5.13M Sell
71,088
-1,460
-2% -$101K 0.18% 62
2014
Q3
$4.49M Sell
72,548
-1,500
-2% -$95.4K 0.16% 71
2014
Q2
$4.72M Sell
74,048
-1,664
-2% -$101K 0.17% 66
2014
Q1
$4.66M Sell
75,712
-300
-0.4% -$17.5K 0.17% 62
2013
Q4
$4.36M Buy
76,012
+1,760
+2% +$99.8K 0.16% 64
2013
Q3
$3.95M Sell
74,252
-6,700
-8% -$361K 0.16% 62
2013
Q2
$4.17M Buy
+80,952
New +$4M 0.17% 60

Other funds holding MDT

Everett Harris & Co's MDT Position: Q2 2026 in Review

Everett Harris & Co increased its Medtronic (MDT) stake by 13% in Q2 2026, buying an estimated $568K and bringing the position to 61,038 shares worth $4.78M. The position accounts for 0.06% of the portfolio, ranked #81.

Everett Harris & Co first reported a position in MDT in Q2 2013 and has held it in 53 quarters since. The position peaked at $22M in Q2 2021. 2,132 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • Everett Harris & Co held 61,038 shares of Medtronic worth $4.78M as of Q2 2026.
  • Everett Harris & Co bought 7,045 Medtronic shares in Q2 2026, an estimated $568K.
  • Medtronic made up 0.06% of Everett Harris & Co's portfolio in Q2 2026, its #81 holding.
  • Everett Harris & Co first reported a position in Medtronic in Q2 2013 and has held it in 53 quarters since.
  • Everett Harris & Co's Medtronic position peaked at $22M in Q2 2021.
  • 2,132 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on Everett Harris & Co's 13F filing for Q2 2026, filed 3 Aug 2026.